{"protocolSection":{"identificationModule":{"nctId":"NCT06189209","orgStudyIdInfo":{"id":"RP6530-2301"},"organization":{"fullName":"Rhizen Pharmaceuticals SA","class":"INDUSTRY"},"briefTitle":"Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)","officialTitle":"A Phase II, Multi-center, Single-arm, Open-label Study to Assess the Efficacy and Safety of Tenalisib, a PI3K δ/γ, and SIK3 Inhibitor, in Patients With Metastatic Triple Negative Breast Cancer (TNBC)"},"statusModule":{"statusVerifiedDate":"2025-03","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-03-04","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-10-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-12-08","studyFirstSubmitQcDate":"2023-12-19","studyFirstPostDateStruct":{"date":"2024-01-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-03-07","lastUpdatePostDateStruct":{"date":"2025-03-11","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Rhizen Pharmaceuticals SA","class":"INDUSTRY"},"collaborators":[{"name":"Incozen Therapeutics Pvt Ltd","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting."},"conditionsModule":{"conditions":["Triple Negative Breast Cancer (TNBC)"],"keywords":["RP6530","Tenalisib"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":40,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Single arm, Open label study","type":"EXPERIMENTAL","description":"Single agent Tenalisib \\[RP6530 (PI3k delta, gamma and SIK3 inhibitor)\\]","interventionNames":["Drug: Tenalisib"]}],"interventions":[{"type":"DRUG","name":"Tenalisib","description":"Tenalisib will be administered 800mg/ 400mg BID, orally","armGroupLabels":["Single arm, Open label study"],"otherNames":["RP6530"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Clinical Benefit Rate (CBR)","description":"It is defined as the percentage of patients achieving complete response (CR), partial response (PR), or stable disease (SD) for 16 weeks or longer.","timeFrame":"1 year"},{"measure":"Duration of Clinical Benefit (DoCB)","description":"It is defined as the time from the first dose to disease progression or death on study from any cause, whichever occurs first in patients who achieve CR, PR or SD for 16 weeks or longer.","timeFrame":"1 year"},{"measure":"Overall Response Rate (ORR)","description":"Overall Response is defined as sum of CR and PR.","timeFrame":"1 year"},{"measure":"Progression Free Survival (PFS)","description":"It is defined as the time from the first dose to disease progression or death on study from any cause, whichever occurs first.","timeFrame":"1 year"}],"secondaryOutcomes":[{"measure":"Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0","description":"Number of adverse events reported by the patients","timeFrame":"1 year"},{"measure":"Trough plasma concentrations of tenalisib/metabolite","description":"plasma concentrations of drug","timeFrame":"1 year"},{"measure":"Correlation of efficacy to baseline mutational status","description":"Baseline mutational status and its correlation with efficacy","timeFrame":"1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients who have histologically confirmed TNBC.\n2. Patients who have received at least 1 but not more than 3 prior chemotherapy regimens in a metastatic setting.\n3. Patients with at least one measurable lesion, per RECIST version 1.1 at baseline . Bone-only disease is not permitted.\n4. ECOG performance status 0 to 2.\n5. Adequate bone marrow, liver, and renal function\n\nExclusion Criteria:\n\n1. Cancer therapy/ any cancer investigational drug within 3 weeks (21 days) or 5 half-lives (whichever is shorter).\n2. Patient who has not recovered from acute toxicities of previous therapy except treatment-related alopecia.\n3. Prior exposure to PI3K inhibitors (e.g., alpelisib, buparlisib) for breast cancer.\n4. Major surgery within 4 weeks of starting study treatment.\n5. Patient with symptomatic uncontrolled brain metastasis.\n6. Ongoing immunosuppressive therapy including systemic corticosteroids.\n7. History of severe cutaneous reactions.\n8. Concurrent disease or condition that would interfere with study participation\n9. Pregnancy or lactation.\n10. Any severe and/or uncontrolled medical conditions or other conditions that could affect patient participation","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Prajak Barde, MD","role":"CONTACT","phone":"+41325800175","email":"pjb@rhizen.com"}],"locations":[{"facility":"HCG City Cancer Center","status":"RECRUITING","city":"Vijayawada","state":"Andhra Pradesh","zip":"520002","country":"India","contacts":[{"name":"Dr. Priyadarshini Lakshmi","role":"CONTACT"}],"geoPoint":{"lat":16.50745,"lon":80.6466}},{"facility":"Narayana Hrudayala Majumdar Shaw Hospital","status":"RECRUITING","city":"Bangalore","state":"Karnataka","zip":"560099","country":"India","contacts":[{"name":"Dr. Nidhi Tandon","role":"CONTACT"}],"geoPoint":{"lat":12.97194,"lon":77.59369}},{"facility":"Tata Memorial Centre","status":"RECRUITING","city":"Mumbai","state":"Maharashtra","zip":"400012","country":"India","contacts":[{"name":"Dr. Sudeep Gupta","role":"CONTACT"}],"geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Mumbai Oncocare Centre","status":"RECRUITING","city":"Mumbai","state":"Maharashtra","zip":"400056","country":"India","contacts":[{"name":"Dr. Ashish Joshi","role":"CONTACT"}],"geoPoint":{"lat":19.07283,"lon":72.88261}},{"facility":"Sahyadri Super Speciality Hospital","status":"RECRUITING","city":"Pune","state":"Maharashtra","zip":"411004","country":"India","contacts":[{"name":"Dr. Tushar Patil","role":"CONTACT"}],"geoPoint":{"lat":18.51957,"lon":73.85535}},{"facility":"Meenakshi Mission Hospital & Research Center","status":"NOT_YET_RECRUITING","city":"Madurai","state":"Tamil Nadu","zip":"625107","country":"India","contacts":[{"name":"Dr. Saju SV","role":"CONTACT"}],"geoPoint":{"lat":9.91769,"lon":78.11898}},{"facility":"Nizams Institute of Medical Science","status":"NOT_YET_RECRUITING","city":"Hyderabad","state":"Telangana","zip":"500082","country":"India","contacts":[{"name":"Dr. Sadashivudu Gundeti","role":"CONTACT"}],"geoPoint":{"lat":17.38405,"lon":78.45636}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-07-07"},"conditionBrowseModule":{"meshes":[{"id":"D001943","term":"Breast Neoplasms"},{"id":"D064726","term":"Triple Negative Breast Neoplasms"}],"ancestors":[{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D001941","term":"Breast Diseases"},{"id":"D012871","term":"Skin Diseases"}],"browseLeaves":[{"id":"M5220","name":"Breast Neoplasms","asFound":"Breast Cancer","relevance":"HIGH"},{"id":"M30373","name":"Triple Negative Breast Neoplasms","asFound":"Triple Negative Breast Cancer","relevance":"HIGH"},{"id":"M5218","name":"Breast Diseases","relevance":"LOW"},{"id":"M15674","name":"Skin Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC17","name":"Skin and Connective Tissue Diseases"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"meshes":[{"id":"C000706530","term":"Tenalisib"}],"ancestors":[{"id":"D000081082","term":"Phosphoinositide-3 Kinase Inhibitors"},{"id":"D004791","term":"Enzyme Inhibitors"},{"id":"D045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M258756","name":"Tenalisib","asFound":"Corneal topography","relevance":"HIGH"},{"id":"M2270","name":"Phosphoinositide-3 Kinase Inhibitors","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}